CyBio AG: Sales increased

02-Feb-2005

CyBio AG finished the year 2004 with 12.5 Mio. EUR in sales (plus 3.3 percent over previous year). Loss from operation has been reduced significantly in the second half of the year. Cash flow and operational results (EBIT) for the fourth quarter were positive. Compared to prior years loss from operation, 2004 result will be significantly better. With its operating business CyBio increased its cash by 1 Mio. EUR . Liquid funds of the Group at year end amounted to 4.3 Mio. EUR (prior year 3.3 Mio. EUR ).

Last week CyBio signed a long term agreement with CLONDIAG chip technologies GmbH for delivery of an automatic pipetting and analyzing instrument for the laboratory diagnostics industry. CyBio AG will publish the audited financial statement of 2004 on 30th March, 2005.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures